Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

CPX-351 is a liposomal formulation of cytarabine:daunorubicin designed to deliver synergistic drug ratios to leukemia cells. In this phase 2 study, newly diagnosed older acute myeloid leukemia (AML) patients were randomized 2:1 to first-line CPX-351 or 7+3 treatment. The goal was to determine effica...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood
Main Authors: Lancet, Jeffrey E., Cortes, Jorge E., Hogge, Donna E., Tallman, Martin S., Kovacsovics, Tibor J., Damon, Lloyd E., Komrokji, Rami, Solomon, Scott R., Kolitz, Jonathan E., Cooper, Maureen, Yeager, Andrew M., Louie, Arthur C., Feldman, Eric J.
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2014
主題:
Clinical Trials and Observations
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4624448/
https://ncbi.nlm.nih.gov/pubmed/24687088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-12-540971
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍